Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics Plc ADR (NQ: AUTL )

4.995 +0.155 (+3.20%)
Streaming Delayed Price Updated: 12:43 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Autolus Therapeutics Plc ADR

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. 
Via Talk Markets
Analyst Expectations for Autolus Therapeutics's Future
Via Benzinga
Where Autolus Therapeutics Stands With Analysts
Via Benzinga
Preview: Autolus Therapeutics's Earnings
Via Benzinga
The Latest Analyst Ratings for Autolus Therapeutics
Via Benzinga
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
Autolus Therapeutics's Earnings Outlook
Via Benzinga
Earnings Outlook For Autolus Therapeutics
Via Benzinga
Why Autolus Therapeutics Stock Is Crashing Today
The biopharmaceutical company announced the pricing of a secondary stock offering. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9  
Via Benzinga
3 Top Penny Stock Picks You Haven’t Heard Of
Here are three penny stock picks investors likely haven't heard of, but probably should keep on the radar as speculative options. 
Via InvestorPlace
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Tesla To Rally More Than 12%? Here Are 10 Other Analyst Forecasts For Wednesday
HC Wainwright & Co. cut the price target for DURECT Corporation (NASDAQ: DRRX) from $35 to $32. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. DURECT shares fell 1.3% to close at $4.75 on... 
Via Benzinga
Dow Tumbles 100 Points; Silver Rises Over 2%
U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday 
Via Benzinga
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate. 
Via Benzinga
US Stocks Turn Higher; Nasdaq Rises 40 Points
U.S. stocks traded slightly midway through trading with the Nasdaq gaining over 40 points on Friday 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
US Stocks Edge Lower; Producer Prices Increase Higher Than Expected
U.S. stocks traded slightly lower this morning following the release of PPI data 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Autolus Therapeutics' Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital Raise
Via Benzinga
Why Autolus Therapeutics Shares Are Trading Lower By Around 26%; Here Are 28 Stocks Moving Premarket
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 48.2% to $6.03 in pre-market trading after jumping over 20% on Thursday. Baudax Bio initiated Phase II clinical trial evaluating BX1000 in patients... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
The trading week is almost complete but we've still got the biggest pre-market stock movers to go over for Friday morning! 
Via InvestorPlace
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.